Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.

Vaccine immunotherapy targeting interleukin 6 (IL-6) has shown promising results in the treatment of inflammatory osteoarthritis of the knee, according to a phase 1 double-blind controlled study.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Some patients are suboptimal responders to anti-VEGF ...